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Introduction 
 
Since antiquity, microbial fermentation processes have been 
extensively used for the processing of foods and the production of 
beverages, while technological developments over the past century 
made microbes the work-horses for large scale industrial production 
processes. Since the 1980s in particular, significant advances in 
genetic engineering have converted microbes to “cell factories” for the 
production of a diverse range of important chemical compounds. 
Manipulation of microbial metabolism holds major advantages, since 
microbes offer an environmentally friendly means to efficiently 
convert cheap raw materials like glucose, sucrose, and biomass derived 
materials into high value chemicals and fuels. Saccharomyces cerevisiae 
is an organism highly preferred by the industry, as it can withstand 
high osmotic pressure and reduced pH compared to bacteria [1]. 
Currently, there is continuous development and improvement of yeast 
strains for the production of high levels of desirable end products. 
The pace of strain development has accelerated as new tools for 
metabolic engineering manipulations are introduced. The overall 
approach for generating high production strains is currently based on 
a number of complementary approaches that include: a) the 
upregulation of desirable biosynthetic pathways, b) the suppression of 
pathways that drain resources or precursors (competing pathways), c) 
the introduction of exogenous genes or biosynthetic pathways, and d) 
the development of methodologies to alleviate stress and/or toxicity 
caused by the production of high levels of the product or of an 
undesirable intermediate. The arsenal of the contemporary metabolic 
engineer contains tools that allow for either targeted rational 
interventions that introduce changes in the strain’s genotype based on 
past knowledge of the  biosynthetic  machinery and its regulation, or  
 
 
 
 
 
 
 
 
 
 
global screens that combine classical approaches of strain evolution 
through adaptation and selection with –omics approaches that can 
globally assess changes leading to desirable outputs. 
Efforts to produce terpenoids in S. cerevisiae are characteristic of 
the variety of novel approaches used for strain improvement.  
Terpenoids and isoprenoids are an important class of secondary 
metabolites contributing more than 50,000 compounds to the rich 
chemical diversity of natural product structures [2]. Members of this 
group have attracted commercial interest as flavour and fragrance 
additives in the food and cosmetic industry. One such example is 
sclareol, an industrially important diterpene used by the fragrance 
industry [3,4]. Many terpenoids also possess pharmaceutical 
properties and are currently used in clinical practice. Among them 
taxol, a diterpene from yew, which has successfully been established as 
a major antineoplastic agent, and artemisinin, a sesquiterpene lactone, 
which is an effective antimalarial agent [5-10]. Recently, attention has 
also focused on microbially produced terpenes as biodiesel [11-13]. 
Terpenoids are biosynthesized from two C5 precursors, isopentenyl 
diphosphate (IPP) and dimethylallyl diphosphate (DMAPP) [14]. In 
yeast and mammals, IPP originates from acetyl-CoA through the 
intermediate mevalonic acid (MVA). IPP then gives rise through the 
action of prenyltransferase enzymes to the higher order building 
blocks, geranyl pyrophosphate (GPP; C10), farnesyl pyrophosphate 
(FPP; C15) and geranylgeranyl pyrophosphate (GGPP; C20) [14]. In 
yeast, most of the pathway output in the form of FPP is utilized for 
the biosynthesis of sterols. Sterols are essential structural and 
regulatory components of eukaryotic cell membranes. Ergosterol, the 
main sterol in yeast, is responsible for structural membrane features 
such as fluidity and permeability, in a similar way as cholesterol is in 
human cells [15]. The pathway has been extensively studied for 
several years, since it functioned as a model for understanding human 
disease caused by high cholesterol levels [16] and is target of an 
important class of antifungal compounds [16]. Extensive knowledge 
on the biosynthesis and regulation of the pathway provided the first 
set of targeted interventions to increase the pool of the intermediates 
GPP, FPP, and GGPP, which are the substrates of terpene synthases.  
The terpene hydrocarbon scaffolds are generated by the action of 
mono-,   sesqui-,  and  diterpene  synthases  that  catalyze  multi-step  
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reactions with diphosphorylated substrates of 10 (GPP), 15 (FPP) or 
20 (GGPP) carbon atoms. The reactions catalyzed by terpene 
synthases are unparalleled relative to other classes of enzymes because 
they often consist of a series of stereochemically complex steps. These 
reactions initiate by the ionization of the diphosphate substrate to 
create an acyclic and reactive carbocationic intermediate. Subsequent 
regio- and stereo-specific formation of single or multiple rings, proton 
eliminations to form double bonds, water quenching of carbocations 
to create terpene alcohols, and stereospecific hydride, methyl, and 
methylene migrations, give rise to a vast complexity of structures 
[17,18]. All this chemical complexity is catalyzed by enzymes whose 
three dimensional structure is highly conserved from fungi to plants, 
characterized by an active site lined mainly by inert amino acids [18]. 
Yeast does not normally produce terpenoids. However, expression of 
plant derived terpene synthases in yeast cells showed that it was 
possible for the enzymes to utilize the endogenous substrates (GPP, 
FPP, GGPP) and produce a range of terpenoid compounds [9,19,20]. 
The number of terpenoids produced is continuously growing as new 
genes from plant sources are cloned and characterized [21-26]. 
Following the formation of the olefin structure of terpenes, the 
metabolites can be further modified in nature by various cytochrome 
P450-dependent mono-oxygenases (P450), reductases, 
dehydrogenases or various classes of transferases, which expands 
immensely the variety of chemical structures synthesized [27]. Yeast, 
is the preferred host for P450 expression as it can express functionally 
active plant derived P450 enzymes [9,28-30].  
 
Targeted interventions in the yeast MVA pathway to increase 
the terpene substrate pool 
 
HMG-CoA reductase (3-hydroxy-3-methyl-glutaryl-CoA 
reductase; HMGR) is the key enzyme of the MVA pathway. The 
HMGR-catalyzed reaction produces mevalonic acid from HMG-CoA 
by reduction with NADPH (Figure 1). Statins, a class of top-selling 
drugs for lowering cholesterol, target HMGR [31]. Yeast possesses 
two enzymes of HMGR, Hmg1p and Hmg2p, which share a similar 
structure to the mammalian and plant counterparts composed of an 
N-terminal eight-helix spanning domain, a linker, and a C-terminal 
catalytic domain. Between the two enzymes Hmg1p is considered 
quite stable whereas Hmg2p undergoes mevalonate products-induced 
degradation [32]. A variety of early studies had pointed out that 
increased levels of pathway products led to degradation of Hmg 
proteins, lowering production levels [33,34]. As a first step towards 
sterol-overproducing strains, Polakowski and co-workers used a 
deregulated version of Hmg1p [35]. The gene was truncated and the 
soluble tHmg1p catalytic domain was overexpressed, causing 
accumulation of a large amount of squalene [35].  Overexpression of 
tHMG1 was applied to improve amorphadiene levels produced in 
yeast [9]. It has since become a basic tool for intervention to the 
MVA pathway, either by expressing tHMG1 episomally or by 
integrating it into the chromosome [10,25,36,37]. Alternatively, our 
lab used a stable variant of Hmg2p which harbors a point mutation 
substituting Lysine 6 by an Arginine (K6R), thus rendering the 
enzyme resistant to ubiquitination. Expression of HMG2 (K6R) had 
equivalent effects in enhancing monoterpene and sesquiterpene 
production [21]. The extent by which proper subcellular localization 
of Hmg proteins on the perinuclear membrane of the engineered 
strains may affect their function is not yet clear. However, we have 
recently identified a set of gene perturbations which lead to increased 
stabilization of the endogenous Hmg proteins and to dramatic 
improvements in sesquiterpene production that could not be achieved 
by tHmg2p overproduction alone (Ignea, submitted).  
 
  
The ERG9 gene codes for squalene synthase, the enzyme that 
joins two FPP moieties to form squalene in the first committed step 
Figure 1. Synopsis of terpene biosynthesis in yeast indicating the genes involved and the metabolic engineering interventions employed. Upregulated yeast 
genes indicated indicated in green, downregulated yeast genes in red.  Genes whose products have been fused or attached to a synthetic protein scaffold are 
denoted with supersripted (f).  Enzymes with product yield or specificity improved or altered by protein engineering are indicated by superscripted (e). (CPP, 
copalyl diphosphate; CDS, copalyl diphosphate synthase; DTS, diterpene synthase; MTS, monoterpene synthase; SeACS(L641P), Salmonella enterica acetyl-CoA 
synthase mutant L641P; AtoB, acetoacetyl-CoA synthase/thiolase).  
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of the sterol biosynthetic pathway. Squalene formation is the major 
draining route of isoprenoid substrates, and as such its suppression is 
desirable. Since deletion of ERG9 is lethal, complete elimination of 
squalene synthesizing activity is not feasible. Studying Hmg2p 
regulation, Gardner and Hampton [38], used a tunable MET3 
promoter (PMET3) to replace the endogenous ERG9 promoter. 
Addition of methionine in the medium at concentrations >0.5 mM 
suppressed the transcription of ERG9 [32]. The same approach was 
taken by Ro et al. [9], who used ERG9 suppression, under conditions 
of tHMG1 overexpression, to achieve an additional 2-fold 
improvement in the levels of amorphadiene production. Suppression 
of ERG9 through the use of a PMET3 promoter was also used in an 
effort to increase production of the sesquiterpenes cubebol, valencene 
and patchoulol [33]. In this study, the introduction of the PMET3 
promoter was less efficient than anticipated and a concomitant 
increase in farnesol formation, as by-product, was observed. This 
raised the issue of tightness of PMET3 regulation due to consumption 
of methionine in the medium [20]. A recent study addressed this issue 
by testing fusions of the PMET3 to the lacZ gene and monitored β-
galactosidase activity of the strain growing under different regiments 
of methionine supplementation [24]. In the cultures that contained L-
methionine, LacZ activity was initially very low. However, at about 
mid-exponential phase, it started to increase and rapidly reached levels 
measured in the non-repressed cultures [24]. To provide a tighter 
control of ERG9 expression, the glucose regulated promoters PHTX1 
and PHTX2 were tested, aiming to maintain moderate expression of 
ERG9 during exponential growth and maximal repression during 
glucose limited conditions in a batch cultivation process. PHTX1 was 
shown to be efficient in downregulating ERG9 expression under 
glucose limiting conditions. An alternative to using promoters with 
varying strengths and inducibility was based on posttranscriptional 
mechanisms controlling mRNA stability [39]. A set of hairpin 
sequence modules recognized by the RNAase III enzyme Rnt1p can 
be inserted at the 3'UTR of a gene to regulate transcript stability. 
With decreasing transcript levels, a similar decrease in protein levels 
was observed. This strategy was tested on ERG9 and depending on 
the hairpin module used, achieved a level of suppression ranging 
between 40%-100% of control transcript levels.  In an additional 
approach to suppress ERG9 transcript levels, our lab tested the 
heterozygous deletion of the gene in a diploid strain, aiming to 
capitalize on previous observations revealing that in yeast loss of the 
one allele leads in the vast majority of cases to almost 50% reduction 
in protein levels [40]. Co-expression of HMG2(K6R) together with 
erg9/ERG9 haploinsufficiency increased the production of 
monoterpenes and sesquiterpenes by >4-fold [21]. The approach 
does not require complex media and could be used in a continuous 
fermentation system. It can also be applied to numerous other genes, 
thus downregulating competing biochemical pathways or alleviating 
regulatory restrictions. It would be interesting to test PHTX1 regulation 
in the remaining allele (PHTX1-ERG9/erg9) as the level of repression 
would be tighter.  
 
The Erg20p enzyme catalyzes the condensation of IPP and 
DMAPP to form GPP and subsequently FPP, which is the major 
product. ERG20 overexpression was used to increase amorphadiene 
production but its effect was limited to a 10% increase in total yield 
[9]. A small increase in sesquiterpene production was also observed 
when one allele of ERG20 was controlled by the strong PGAL1 [21]. 
The ratio of GPP:FPP produced in vitro by a cell extract of wild type 
cells was 25:75.  A mutation was identified in lysine 197 of Erg20p 
(K197E) which suppressed the second part of the catalysis resulting 
in reversed ratios 70:30 GPP:FPP [41]. This shift towards GPP 
formation was used to enhance monoterpene formation in yeast cells. 
Expression of geraniol synthase in an ERG20 (K197G) background 
resulted in important improvement in geraniol productivity [42]. 
 
Shiba et al. addressed the bottleneck in the supply of acetyl-CoA 
to the mevalonate pathway, and showed that overproduction of 
acetaldehyde dehydrogenase ALD6 and introduction of a 
heterologous acetyl-CoA synthase variant from Salmonella enterica 
(L641P) together with tHMG1 expression achieved substantial 
improvements in amorphadiene production [43]. 
 
Upc2p and Ecm22p are two highly homologous zinc cluster 
proteins regulating a number of ERG genes in the yeast ergosterol 
biosynthetic pathway. They positively regulate transcription by 
binding to sterol response elements in the promoters of the target 
genes. The upc2-1 mutant contains a single amino acid change 
(G888D) within the activation domain of the protein [44,45]. 
Overexpression of upc2-1 by itself appears to exert modest effects on 
amorphadiene production which become more pronounced in 
combination with tHMG1 and PMET3-ERG9 [9-11]}. 
 
Encodes for IPP isomerase, catalyzing the conversion of IPP to its 
isomer DMAPP. ERG20 adds one molecule of IPP to DMAPP to 
form GPP. In the case of monoterpene production, when a rich GPP 
pool is required, IDI1 overexpression significantly enhanced 
monoterpene titers [21].  
 
Encodes for geranylgeranyl diphosphate synthase. The enzyme 
uses FPP and IPP to synthesize the C20 GGPP substrate used for 
ubiquinone biosynthesis and geranylgeranylation of proteins for 
membrane attachment. GGPP is the substrate for diterpene and 
carotenoid biosynthesis. Overexpression of BTS1 has been combined 
with CrtYB and CrtI from Xanthophyllomyces dendrorhous to 
generate β-carotene and with CrtS to produce astaxanthin [46,47]. 
Bts1p has been fused to Erg20p to improve product yields for 
geranylgeraniol [48,49] and miltiradiene [25]. When the crtE gene, 
which encodes for the GGPP synthase of X. dendrorhous, was co-
expressed with CrtYB and CrtI, significant improvement over BTS1 
was observed [47]. This does not appear to be due to species 
specificity of GGPPS, since we observed a comparably high 
production upon co-expression of CrtYB and CrtI with the plant 
derived Cistus creticus GGPPS1 [50] (unpublished observations). 
 
Inhibition of squalene synthase (SQS) in mammalian species was 
shown to lead to conversion of FPP to farnesol. Farnesol 
accumulation was also seen in yeast strains treated with zaragosic acid, 
a natural inhibitor of SQS [51]. It has been postulated that 
dephosphorylation of FPP and GPP may be a mechanism to alleviate 
the potentially toxic effects of substrate accumulation. Lpp1p and 
Dpp1p, two enzymes initially identified as phosphatidic acid 
hydrolases were shown to also dephosphorylate isoprenoid phosphates 
[52]. Deletion of DPP1 was reported to result in a modest increase of 
the sesquiterpene α-santalene and a 24% drop in farnesol 
accumulation [24]. However, other studies aiming at high 
sesquiterpene production did not observe significant improvements 
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[53,54]. Still, when LPP1 and DPP1 were overexpressed fused to 
BTS1, they exerted a strong positive effect on geranylgeraniol 
production, with DPP1 exerting the strongest effect, yielding 2.9-fold 
higher levels of GGOH than simple co-expression of the genes [49].  
 
Protein engineering to improve product yield and to expand the 
chemical diversity 
 
The primary goals of protein engineering studies to date have 
been to increase product yield and to interfere with the cyclization 
chemistry of the terpene synthases so as to either produce enzymes 
with higher specificity or to derive new products out of a specific 
enzyme. 
 
Improving product yield – Based on the previous observation that 
the two main bottlenecks in terpene biosynthesis in E. coli are caused 
by the poor activities of the HMGR and the terpene synthase [55], 
Yoshikuni and coworkers developed a methodology based on adaptive 
evolution to improve the catalytic efficiency of these two enzymes 
[56]. By comparing the sequences of a large number of central 
metabolic enzymes, they noticed that Gly and Pro were significantly 
less frequently mutated than other amino acids in E. coli enzymes, 
suggesting that these residues may be more essential. They applied 
this finding in the truncated form of HMGR and in an inefficient 
humulene synthase. By switching non-conforming Gly and Pro 
residues to match the consensus sequence, and by saturation 
mutagenesis of the glycines and prolines that did not align, an 
engineered version of tHMGR (tHMGR-G9), which contains nine 
mutated residues, exhibited a 2.5- to 3-fold increase in the production 
of mevalonate compared to the wild-type tHMGR. Similarly, HUM-
G6 (an engineered version of humulene synthase bearing six such 
substitutions) improved sesquiterpene production by 80 fold. 
Integration of the tHMGR-G9 and HUM-G6 mutants into the same 
host resulted into a three- to four-fold improvement in growth, 
leading to an overall improvement in sesquiterpene production by 
nearly 1000 fold [56]. 
Using a colorimetric assay based on the production of lycopene in 
E. coli as a high-throughput screening method, Leonard and co-
workers applied a saturation mutagenesis approach to isolate 
improved Taxus canadensis GGPPS variants [57].  The double 
mutant S239C/G295D improved levopimaradiene production by 
1.7-fold.  To further improve levopimaradiene production, fifteen 
residues constituting the binding pocket of levopimaradiene synthase 
(LPS) were selected based on homology modeling. Perturbation of 
these residues using phylogeny-based mutation, saturating 
mutagenesis, and combination of the beneficial mutations improved 
enzyme productivity by up to 10-fold (some combinations also 
showed an improvement in product specificity, albeit with lower than 
maximal productivity) [57]. 
 
Improving product specificity – To investigate whether a 
promiscuous terpene cyclase can be engineered to have improved 
product selectivity, Yoshikuni and coworkers employed -humulene 
synthase from Abies grandis, an enzyme with an extremely 
promiscuous product proﬁle, synthesizing more than 50 different 
sesquiterpene products. Using homology modeling, they identified 19 
residues which were subsequently altered by saturation mutagenesis. 
By systematically combining different beneficial mutations, a 
collection of more specific terpene synthases was constructed, 
including an E-β-farnesene synthase, a siberene synthase, a β-
bisabolene synthase, a longifolene synthase and an α-longipinene 
synthase [58].  
Expanding product diversity - Until recently, there has been 
insufficient evidence to support the conclusion that a modified 
terpene synthase scaffold can produce entirely novel compounds, 
rather than altered levels of compounds already made by the parent 
scaffold.  Although the large scale mutagenesis of A. grandis -
humulene synthase mentioned above yielded mutant synthases with 
narrower product specificity, it failed to produce structures not 
synthesized by the wild-type enzyme [58].  However, this approach 
used a mathematical model to predict changes that would improve 
specificity for certain compounds and this may have influenced this 
screen against the identification of new entities. The first evidence for 
the ability of a terpene synthase scaffold to acquire a new specificity 
came through a concentric mutagenesis approach aiming to 
interconvert the activities of tobacco 5-epi-aristolochene synthase 
(TEAS) and Hyoscyamus muticus premnaspirodiene synthase (HPS).  
In this study, a combination of second tier residue alterations enabled 
the production of epi-aristolochene by HPS, an activity not present in 
the wild-type enzyme [59].  Our work on the engineering of Salvia 
terpene synthases extended this finding, by demonstrating that a 
monoterpene synthase can be modified to produce sesquiterpenes by a 
single amino acid substitution [60]. In the same study, the Salvia 
pomifera sabinene synthase 1 (Sp-SabS1) was modified to produce 
1,8-cineole and a-terpineol, two products not made by the wild-type 
enzyme.  Subsequent studies extended these observations to diterpene 
synthases, where single residue substitutions converted an isokaurene 
synthase into a specific pimaradiene synthase [61], or a 
levopimaradiene/abietadiene synthase into an isopimaradiene synthase 
[62].  The limited sequence-space explored in these experiments 
makes it possible that significant novel activity can be produced using 
more thorough mutagenesis approaches. 
 
Metabolic channeling by fusion enzymes 
 
The generation of fused enzymes has been proposed as a means to 
minimize losses of intermediate products through diffusion, 
degradation, or utilization by rival enzymes. This could be especially 
important when exogenous enzymes, such as terpene synthases 
(TPSs), are used. Fusions of Erg20p to TPSs were tested for the 
production of patchoulol and exhibited higher yields than the separate 
enzymes [53]. Not all fusions appear to result in a net gain, since 
some enzymes are also sensitive to their placement in the fusion. We 
noted that a C-terminal fusion of EYFP to a sesquiterpene synthase 
(STS) caused a significant reduction in enzymatic activity. Similarly, 
no improvement was seen when farnesyl diphosphate synthase (FPPS) 
was fused at the C-terminus of patchoulol synthase (PTS), in contrast 
to the inverse fusion (FPPS-PTS) [53]. Expanding this system, a dual 
fusion strategy was employed by Zhou and colleagues for the 
production of the diterpene miltradiene. The Bts1 protein was fused 
to the N-terminus of Erg20p to drive efficient GGPP production, 
while copalyl diphosphate (CPP) synthase was appended to the C-
terminus of miltiradiene synthase to provide the latter with ample 
adequate CPP substrate [25].  A parallel approach fused FPPS and 
STS genes to the COX4 mitochondrial targeting sequence, aiming to 
target the pathway to the organelles where FPP pools are naturally 
present. When combined with cytosolic tHMG1 overexpression, an 
extra boost in sesquiterpene production was observed [63].  
An alternative approach to fusion proteins was applied to the 
mevalonate pathway by attachment of protein interaction domains 
and their respective peptide ligands. Expression of yeast HMGR and 
HMG-CoA synthase (HMGS) attached to the SH3 domain and the 
SH3 ligand respectively in E. coli improved mevalonate yields [64]. 
The protein interaction domains were also built into a synthetic 
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scaffold module (GBD-SH3-PDZ domains) and AtoB (Acetoacetyl-
CoA thiolase, native to E. coli), HMGS and HMGR were fused to 
the corresponding peptide ligands. This co-recruitment of proteins 
increased production of mevalonate dramatically (77-fold) [64]. As 
the number of terpene decorating enzymes introduced in yeast 
increases, the scaffold approach could provide the desirable 
biosynthetic pathway efficiency. 
 
Coping with stress 
 
Increased production of terpenes, especially oxidized compounds 
is expected to impose stress on the cellular machinery. Examination of 
cells producing artemisinic acid for induction of pleiotropic drug 
resistance revealed high induction of the ABC transporters PDR5, 
PDR15, YOR1, and SNQ2 [65]. Identification of plant-pathway 
components which participate in biosynthesis and transport of 
terpenoids could be an additional means to relieve the stress imposed 
on the yeast cell by high production. We previously identified a plant 
HSP90 by two-hybrid assays, which interacted with the monoterpene 
cineole synthase (SfCinS1). Co-expression of the HSP90 and 
SfCinS1 in yeast cells contributed to a modest, albeit consistent, 
improvement in cineole production [21]. Presumably additional plant 
genes can be tested for their contribution to terpene biosynthesis in 
yeast cells.  
 
Global approaches to strain improvement 
 
The development of –omics technologies and advanced modeling 
tools has enabled global approaches which could illuminate the 
genetic basis of phenotypic diversity. Such an approach was applied to 
assess the differences in ergosterol production between widely used 
lab strains. One such strain is CEN.PK113-7D which is becoming a 
strain of choice for terpenoid production. The strain was fully 
sequenced, annotated and compared to the 288c reference genome to 
identify single nucleotide polymorphisms (SNP) which could be 
informative on the nature of changes taken place in the ergosterol 
pathway. Focusing only on metabolic genes, 85 out of 219 SNPs 
were encoding for amino acid changes (non-synonymous or non-
silent) [66]. A number of SNPs were identified in the genes ERG8 
(phosphomevalonate kinase), ERG9 and HFA1 (mitochondrial acetyl 
co-enzyme A carboxylase catalyzing the production of malonyl-CoA 
in fatty acid biosynthesis). Co-expressed with β-amyrin synthase with 
combinations of these variants led to a 5-fold improvement in amyrin 
production [67].   
Another computational approach based on a minimization of 
metabolic adjustments algorithm (MOMA), identified GDH1 as a 
possible target which could shift the metabolic flux towards the 
ergosterol pathway. The gene encodes a glutamate dehydrogenase 
involved in ammonium metabolism in yeast and requires NADPH for 
its function. The conversion of HMG-CoA to mevalonate is an 
NADPH requiring step, thus deletion of GDH1 was postulated to be 
beneficial for carbon flux through the mevalonate pathway by 
increasing the pool of available NADPH for HMGR. In yeast there 
are two other glutamate dehydrogenase enzymes encoded by GDH2 
and GDH3. GDH3 appears to have arisen from genome duplication 
of GDH1, while GDH2, unlike the other two, is an NADH-
dependent enzyme. Deletion of GDH1 in cells expressing cubebol 
synthase led to approximately 85% increase in the final titer [68]. 
However, despite the presence of the other two GDH enzymes, gdh1 
causes severe growth impediments [68]. An approach to suppress but 
not eliminate protein levels could be effective without the side effects. 
Recently, we tested heterozygous deletions of GDH1 alone or in 
combinations with other haploinsufficiencies and observed a modest 
but consistent increase in sesquiterpene production (Ignea, 
submitted). Being complementary to approaches focused on the 
biosynthetic components, as the production yield increases, 
suppression of GDH1 may become more important.  
The dramatic reductions in sequencing costs and the rapid 
development of new computational tools will contribute to classical 
strain improvement approaches using evolution and adaptation by 
providing feedback on the genetic changes that take place and cannot 
be assessed by metabolic flux models or rational design approaches. 
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